Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

套细胞淋巴瘤 自体干细胞移植 伊布替尼 医学 移植 美罗华 长春新碱 肿瘤科 内科学 切碎 环磷酰胺 淋巴瘤 胃肠病学 外科 化疗 白血病 慢性淋巴细胞白血病
作者
Martin Dreyling,Jeanette K. Doorduijn,Eva Giné,Mats Jerkeman,Jan Walewski,Martin Hutchings,Ulrich Mey,Jon Riise,Marek Trněný,Vibeke Vergote,Ofer Shpilberg,María Gomes da Silva,Sirpa Leppä,Linmiao Jiang,Stephan Stilgenbauer,Andrea Kerkhoff,Ron D. Jachimowicz,Melania Celli,Georg Heß,Luca Arcaini
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10441): 2293-2306 被引量:40
标识
DOI:10.1016/s0140-6736(24)00184-3
摘要

BackgroundAdding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT.MethodsThe open-label, randomised, three-arm, parallel-group, superiority TRIANGLE trial was performed in 165 secondary or tertiary clinical centres in 13 European countries and Israel. Patients with previously untreated, stage II–IV mantle cell lymphoma, aged 18–65 years and suitable for ASCT were randomly assigned 1:1:1 to control group A or experimental groups A+I or I, stratified by study group and mantle cell lymphoma international prognostic index risk groups. Treatment in group A consisted of six alternating cycles of R-CHOP (intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous cyclophosphamide 750 mg/m2 on day 1, intravenous doxorubicin 50 mg/m2 on day 1, intravenous vincristine 1·4 mg/m2 on day 1, and oral prednisone 100 mg on days 1–5) and R-DHAP (or R-DHAOx, intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous or oral dexamethasone 40 mg on days 1–4, intravenous cytarabine 2 × 2 g/m2 for 3 h every 12 h on day 2, and intravenous cisplatin 100 mg/m2 over 24 h on day 1 or alternatively intravenous oxaliplatin 130 mg/m2 on day 1) followed by ASCT. In group A+I, ibrutinib (560 mg orally each day) was added on days 1–19 of R-CHOP cycles and as fixed-duration maintenance (560 mg orally each day for 2 years) after ASCT. In group I, ibrutinib was given the same way as in group A+I, but ASCT was omitted. Three pairwise one-sided log-rank tests for the primary outcome of failure-free survival were statistically monitored. The primary analysis was done by intention-to-treat. Adverse events were evaluated by treatment period among patients who started the respective treatment. This ongoing trial is registered with ClinicalTrials.gov, NCT02858258.FindingsBetween July 29, 2016 and Dec 28, 2020, 870 patients (662 men, 208 women) were randomly assigned to group A (n=288), group A+I (n=292), and group I (n=290). After 31 months median follow-up, group A+I was superior to group A with 3-year failure-free survival of 88% (95% CI 84–92) versus 72% (67–79; hazard ratio 0·52 [one-sided 98·3% CI 0–0·86]; one-sided p=0·0008). Superiority of group A over group I was not shown with 3-year failure-free survival 72% (67–79) versus 86% (82–91; hazard ratio 1·77 [one-sided 98·3% CI 0–3·76]; one-sided p=0·9979). The comparison of group A+I versus group I is ongoing. There were no relevant differences in grade 3–5 adverse events during induction or ASCT between patients treated with R-CHOP/R-DHAP or ibrutinib combined with R-CHOP/R-DHAP. During maintenance or follow-up, substantially more grade 3–5 haematological adverse events and infections were reported after ASCT plus ibrutinib (group A+I; haematological: 114 [50%] of 231 patients; infections: 58 [25%] of 231; fatal infections: two [1%] of 231) compared with ibrutinib only (group I; haematological: 74 [28%] of 269; infections: 52 [19%] of 269; fatal infections: two [1%] of 269) or after ASCT (group A; haematological: 51 [21%] of 238; infections: 32 [13%] of 238; fatal infections: three [1%] of 238).InterpretationAdding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined.FundingJanssen and Leukemia & Lymphoma Society.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
RC_Wang应助科研通管家采纳,获得10
刚刚
刚刚
共享精神应助Volcano采纳,获得10
4秒前
4秒前
4秒前
ali完成签到,获得积分20
5秒前
han发布了新的文献求助10
6秒前
大个应助无限雨南采纳,获得10
7秒前
丘比特应助幽默尔蓝采纳,获得10
7秒前
EED发布了新的文献求助10
8秒前
8秒前
yy完成签到,获得积分10
9秒前
9秒前
9秒前
李爱国应助十三儿采纳,获得10
10秒前
ali发布了新的文献求助10
11秒前
11秒前
HOME发布了新的文献求助10
13秒前
熊大哥发布了新的文献求助10
15秒前
16秒前
科研马完成签到,获得积分10
17秒前
猫和老鼠发布了新的文献求助10
18秒前
18秒前
19秒前
发篇Sci不过分吧完成签到,获得积分20
19秒前
奥特超曼应助易槐采纳,获得10
21秒前
21秒前
上官若男应助Supreme采纳,获得10
21秒前
熊大哥完成签到,获得积分10
21秒前
21秒前
22秒前
小蘑菇应助威武的手链采纳,获得10
22秒前
可爱千兰完成签到,获得积分10
22秒前
十三儿完成签到,获得积分20
22秒前
23秒前
23秒前
木木发布了新的文献求助20
23秒前
重要鑫磊完成签到,获得积分10
25秒前
25秒前
ccc发布了新的文献求助10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988920
求助须知:如何正确求助?哪些是违规求助? 3531290
关于积分的说明 11253247
捐赠科研通 3269903
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882027
科研通“疑难数据库(出版商)”最低求助积分说明 809052